# SHR-1701 Combined with SHR2554 and BP102 for MCRC

Source: https://onco.cc/trials/nct06679673/  
OnCo record `nct06679673` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of retlirafusp alfa in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

SHR-1701 Combined with SHR2554 and BP102 for MCRC is a phase 2, interventional study registered as NCT06679673 by Fudan University, with a registry enrolment figure of 20 participants, started 2024-12 and due to reach its primary completion in 2025-12. Interventions recorded: SHR-1701; BP102; SHR2554. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "* Histological confirmed metastatic colorectal cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06679673
- Phase: 2
- Setting: An Explorative Study of SHR-1701 Combined with SHR2554 and BP102(bevacizumab) for Metastatic Colorectal Cancer.
- Sponsor: Fudan University
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06679673: https://clinicaltrials.gov/study/NCT06679673

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06679673.json